Tecentriq (Atezolizumab) – ES-SCLC | DengYue Medicine

Tecentriq Application Scope

Tecentriq is a PD-L1 blocking monoclonal antibody used in various advanced cancers.

Characteristics

• Ingredients: Atezolizumab (humanized IgG1κ monoclonal antibody against PD-L1)

• Properties:

  • An immune checkpoint inhibitor that blocks PD-L1 on tumor and immune cells

  • Restores T-cell antitumor activity

• Packaging Specification: 1200 mg/20 mL concentrate for IV infusion

• Storage:

  • Store vials in the original carton, protected from light

  • Diluted IV form: stable 30 days at 2–8 °C and 24 h at 30 °C ambient light

• Expiry Date: As printed on carton; typical shelf-life 18–24 months (check batch label)

• Executive Standard:

  • Meets ATC code L01FF05

  • Complies with FDA and EMA monograph requirements

• Approval Number: FDA initial approval 2016; EU marketing authorization granted April 2017

• Date of Revision: Latest US label update April 2024; Canadian monograph revised January 9, 2025

• Manufacturer:

  • Genentech (a member of Roche Group) – global

  • Packaging by Roche Canada in Ontario

Guidelines for the Use of Tecentriq

• Dosage and Administration:

  • 1200 mg IV over 60 minutes every 3 weeks (subsequent may be 30 minutes if tolerated)

  • Alternative dosing: 840 mg q2w, 1680 mg q4w depending on indication

  • Continue until disease progression or unacceptable toxicity

• Adverse Reactions:

  • Common: fatigue, decreased appetite, nausea, cough, dyspnea, alopecia, GI symptoms

  • Immune-mediated: pneumonitis, colitis, hepatitis, endocrinopathies, nephritis

  • Infusion-related reactions in ~1.3% patients

• Contraindications:

  • None explicitly listed; infusion reactions

  • Immune toxicities are managed by withholding or discontinuation

• Precautions:

  • Monitor for severe immune-mediated events

  • Assess liver, lung, thyroid, and adrenal function

  • Pregnancy – fetal risk; requires effective contraception

  • Withhold or discontinue based on severity

Tecentriq Interactions

• Drug Interactions: No direct pharmacokinetic interactions, but manage immune effects when combined with other immunomodulatory agents

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.